SEC Form 4 · accession 0001209191-17-024356
Xenetic Biosciences, Inc. · XBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James F Parslow
Officer — Chief Financial Officer
Period of report
Apr 3, 2017
Accepted (ET)
Apr 4, 2017 · 8:08 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534525
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $4.57 | Apr 3, 2017 | A | 175,000 | A | — | Apr 3, 2027 | Common Stock | 175,000 | 175,000 | D |
Explanation of responses
- F1The shares underlying the option will vest and become exercisable over three years, with one-third of the underlying shares vesting on each of April 3, 2018, April 3, 2019 and April 3, 2020, subject to the Reporting Person's continuous service with the Issuer through each such date.